Skip to content

Study · Non-randomized trial · n = 47 · 2016

4 results

Investigation of the clinical significance of the growth hormone-releasing peptide-2 test for the diagnosis of secondary adrenal failure.

Arimura H, Hashiguchi H, Yamamoto K, Shinnakasu A, Arimura A, Kikuchi A, Deguchi T, Habu M, Fujio S, Arita K, Nishio Y

Endocrine journal26 Mar 2016Cited by 9 (Europe PMC)

PMID27020037 (opens in a new tab)DOI10.1507/endocrj.ej15-0587 (opens in a new tab)PepBankPUB-27020037
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    Patients with pituitary disorders had significantly lower ACTH responses to the GHRP‑2 test than patients with hypothalamic disorders and the control group.

    In plain wordsPatients with pituitary disorders had a weaker ACTH response to GHRP‑2 than patients with hypothalamic disorders and the control group.

    Peptide
    GHRP-2
    Outcome
    DecreaseACTH response to GHRP-2 test
    Study

    n = 47

    Comparator
    Hypothalamic disorder patients and control group
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Patients with pituitary disorders had significantly lower ACTH responses to the GHRP-2 test compared to patients with hypothalamic disorders and the control group.
    1 context sentence
    Summary · context
    We performed an insulin tolerance test (ITT), CRH stimulation test, and GHRP-2 test on 47 patients suspected of having a hypothalamo-pituitary disorder.
  2. 02HumanNon-randomized trialActivity measurement

    Peak cortisol after the GHRP‑2 test was significantly lower in both hypothalamic and pituitary disorder cases than in the control group.

    In plain wordsPeak cortisol after GHRP‑2 was lower in patients with hypothalamic or pituitary disorders than in the control group.

    Peptide
    GHRP-2
    Outcome
    DecreasePeak cortisol response to GHRP-2 test
    Study

    n = 47

    Comparator
    Control group
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, peak cortisol levels in response to the GHRP-2 test were significantly lower in both hypothalamic and pituitary disorder cases compared with the control group.
    1 context sentence
    Summary · context
    We performed an insulin tolerance test (ITT), CRH stimulation test, and GHRP-2 test on 47 patients suspected of having a hypothalamo-pituitary disorder.
  3. 03HumanNon-randomized trialActivity measurement

    With a cut-off of 11.6 μg/dL for peak cortisol, the GHRP‑2 test predicted secondary hypoadrenalism with 88.9% specificity and 89.7% sensitivity.

    In plain wordsUsing a peak cortisol cut-off after GHRP‑2, the test detected most cases of secondary adrenal failure.

    Peptide
    GHRP-2
    Outcome
    Not applicableDiagnostic accuracy of peak cortisol for secondary hypoadrenalism
    Study

    n = 47

    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Specificity
    88.9%
    cut-off 11.6 μg/dL peak cortisol
    Sensitivity
    89.7%
    cut-off 11.6 μg/dL peak cortisol
    Cut-off peak cortisol
    11.6 μg/dL
    GHRP-2 test

    Source sentences

    Summary
    Assignment of a cut-off value of 11.6 μg/dL for the peak serum cortisol level demonstrated that the GHRP-2 test was able to predict secondary hypoadrenalism with 88.9% specificity and 89.7% sensitivity.
    1 context sentence
    Summary · context
    We performed an insulin tolerance test (ITT), CRH stimulation test, and GHRP-2 test on 47 patients suspected of having a hypothalamo-pituitary disorder.
  4. 04HumanNon-randomized trialActivity measurement

    ACTH and cortisol responses to the GHRP‑2 test had no correlation to the CRH test.

    In plain wordsHormone responses to GHRP‑2 did not match responses to the CRH test.

    Peptide
    GHRP-2
    Outcome
    No significant changeCorrelation of GHRP-2 test responses with CRH test
    Study

    n = 47

    Comparator
    CRH stimulation test
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The responses of ACTH and cortisol to the GHRP-2 test had no correlation to the CRH test, suggesting the involvement of a different mechanism of ACTH secretion.
    1 context sentence
    Summary · context
    We performed an insulin tolerance test (ITT), CRH stimulation test, and GHRP-2 test on 47 patients suspected of having a hypothalamo-pituitary disorder.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.